Foundry Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Foundry Partners’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-282,268	Closed	-$2.09M	–	347
2022 Q4	$2.09M	Buy	+282,268	New	+$2.75M	0.12%	193
2020 Q1	–	Sell	-45,507	Closed	-$747K	–	420
2019 Q4	$747K	Sell	45,507 -1,116	-2%	-$16.9K	0.03%	330
2019 Q3	$619K	Sell	46,623 -110	-0.2%	-$1.53K	0.03%	330
2019 Q2	$658K	Sell	46,733 -144	-0.3%	-$2.29K	0.03%	332
2019 Q1	$863K	Sell	46,877 -3,220	-6%	-$73.4K	0.03%	325
2018 Q4	$1.31M	Sell	50,097 -85	-0.2%	-$2K	0.06%	301
2018 Q3	$1.15M	Sell	50,182 -78	-0.2%	-$1.59K	0.04%	321
2018 Q2	$957K	Sell	50,260 -3,270	-6%	-$54.7K	0.04%	316
2018 Q1	$902K	Sell	53,530 -23,630	-31%	-$396K	0.04%	332
2017 Q4	$1.17M	Sell	77,160 -61,286	-44%	-$910K	0.05%	306
2017 Q3	$2.48M	Buy	+138,446	New	+$2.32M	0.1%	289

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Foundry Partners's VNDA Position: Q1 2023 in Review

Foundry Partners sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 282,268 shares — an estimated $2.09M sold.

Foundry Partners first reported a position in VNDA in Q3 2017 and held it in 11 quarters. The position peaked at $2.48M in Q3 2017. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Foundry Partners reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Foundry Partners sold 282,268 Vanda Pharmaceuticals shares in Q1 2023, an estimated $2.09M.
Foundry Partners first reported a position in Vanda Pharmaceuticals in Q3 2017 and held it in 11 quarters.
Foundry Partners's Vanda Pharmaceuticals position peaked at $2.48M in Q3 2017.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Foundry Partners's 13F filing for Q1 2023, filed 3 May 2023.